Study Protocol: Prospective, Randomized Controlled Trial on the Effect of Primary Resection in Advanced Metastatic NEN of Pancreas and Midgut (PRESNENAS) Abstract #1868

Introduction: The role of Primary Tumor resection in advanced metastatic NEN is discussed controversely.
Aim(s): To show the benefit of primary resection on progression-free survival in advanced metastatic pancreatic and midgut NET (Stage IV) compared to biotherapy
Materials and methods: Well differentiated neuroendocrine neoplasia (NET, G1, G2, Ki-67<10%) of midgut and pancreas with surgically non-resectable metastases and asymptomatic, resectable primary tumor. Comparison between surgical primary resection plus biotherapy and biotherapy only.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Dr. Nehara Begum

To read results and conclusion, please login ...

Further abstracts you may be interested in

#31 Patterns and predictors of failure after curative resections of pancreatic endocrine carcinoma
Introduction: Pancreatic endocrine carcinomas (PECs) are generally associated with a good prognosis, above all after radical resection. In other pancreatic malignancies, predictors of failure and the role of lymph node ratio (LNR) are well-known, but prognostic factors and the value of LNR, as well as patterns of recurrence after surgery for PEC has never been investigated.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Massimo Falconi
#334 Everolimus + Octreotide LAR v. Placebo + Octreotide LAR in Patients With Advanced NET: Results of a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial (RADIANT-2)
Introduction: Everolimus, an oral inhibitor of mTOR, demonstrated promising antitumor activity in patients with NET as a single agent and in combination with octreotide LAR in two phase 2 studies.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Marianne Pavel
#376 Resection of Primary Tumor Improves Survival in Small Bowel Neuroendocrine Tumors: A Single Center Experience
Introduction: Small bowel neuroendocrine tumors are uncommon tumors with an incidence of <0.5-1 per 100,000 population/year. We report on the survival rates of patients who had the primary tumor resected, to see whether primary tumor removal improves outcome.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
#683 Liver Resection Experience for Metastatic Small Bowel NETs, a Single Center Experience
Introduction: Over the last two decades, the role of surgery in the management of small bowel NETs (SBNET) has evolved. There is growing evidence supporting the role of liver resection for metastatic disease.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Raj Srirajaskanthan
#742 Evaluation of Relevant Factors of Prognosis Among a Large German Multi-Centric Cohort–Results from the German NET Registry
Introduction: Neuroendocrine neoplasms (NEN) are a rare tumor entity with varying biological behavior.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Sebastian Maasberg